"Determinants of T Cell Immunity to Tuberculosis Vaccines"
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
批准号:
8049854
负责人:
Steven A Porcelli
金额:
$37.35万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-07-15 至 2016-06-30
关键词:
AdjuvantAnimalsAntigen PresentationAntigensApoptosisApoptoticAttenuatedB-LymphocytesBacillus (bacterium)CD4 Positive T LymphocytesCD8B1 geneCellsChemicalsCore FacilityCosmidsDevelopmentDiseaseFundingGenesGeneticGenetic screening methodGenomeGoalsGrowthHumanImmuneImmune responseImmunityImmunologic Deficiency SyndromesIn VitroInstructionLeadLifeMHC Class II GenesMediatingModificationMolecular AnalysisMulti-Drug ResistanceMutagenesisMutationMycobacterium smegmatisMycobacterium tuberculosisPathway interactionsPhagocytesPreventionPrincipal InvestigatorProductionProtein SubunitsResearchResourcesScreening procedureSpecificitySystemT cell responseT-LymphocyteT-Lymphocyte EpitopesT-Lymphocyte SubsetsTNF geneTuberculosisTuberculosis VaccinesVaccinationVaccinesVertebral columnVirulenceWorkauxotrophycytokinedesign and constructionimmunogenicimmunogenicityimprovedin vivomortalitymutantmycobacterialnovelnovel vaccinesoverexpressionprogramsprotective efficacyresistant strainresponsetuberculosis immunityvaccine candidate
中文摘要
结核分枝杆菌的有效宿主免疫依赖于T细胞介导的抗
杆菌的抗原。我们最近的工作表明,结核分枝杆菌在其基因组中编码
促进宿主免疫逃避或破坏,并通过以下方式干扰有效接种
活的减毒分枝杆菌菌株。在以前的工作中,我们已经确定了多个免疫逃避基因,
并且已经证明它们的失活或缺失可以导致更免疫原性的、减毒的活的
分枝杆菌疫苗在本项目中,我们将在此背景下开发新颖的活M。结核
菌株产生增强的T细胞反应和更强大的保护免疫力在感染的动物。
即使在免疫缺陷的情况下,也会引入突变来消除毒力,
创造原则上可安全广泛用于人类的疫苗株。此外,
我们将使用化学佐剂掺入活分枝杆菌疫苗株,
加强继发性应答以进一步增强疫苗诱导的抗
结核提出了三个具体目标:1)评估M突变的影响。的结核
增强感染宿主细胞对T细胞应答的凋亡; 2)鉴定和表征M.
3)将联合收割机基因修饰与
化学佐剂和加强策略,以增强T细胞应答和由
减毒M.结核病疫苗株。这些研究的长期目标是建立原则,
将导致更安全和更有效的活M。结核病疫苗将有助于控制全球
结核病的负担和减少多药耐药菌株的出现。该项目涉及
本项目的总体目标是通过寻求提高减毒活支原体的免疫原性。
结核病疫苗,并通过建立相关的保护,通过分析特定的细胞
免疫反应。广泛的互动与其他组成部分的政治行动资助计划是
该项目将使sianificantiv受益于poll支持的各种核心资源。
相关性(参见说明):
这项建议是一个计划的组成部分,旨在更详细地了解
结核分枝杆菌逃避宿主免疫而引起严重疾病的机制,
mortality.研究的目标是建立原则,使设计和建设的
更好的预防结核病的疫苗。
英文摘要
Effective host immunity to Mycobacterium tuberculosis is dependent on T cell-mediated responses against
antigens of the bacillus. Our recent work has shown that M.tuberculosis encodes In its genome pathways
that promote evasion or subversion of host immunity, and that these interfere with effective vaccinafion by
live, attenuated mycobacterial strains. In previous work, we have identified multiple immune evasion genes
and have demonstrated that their inactivation or deletion can lead to more immunogenic, attenuated live
mycobacterial vaccines. In this project, we will build on this background to develop novel live M. tuberculosis
strains that generate enhanced T cell responses and more robust protecfive immunity in infected animals.
Mutations will also be introduced to eliminate virulence even in the setting of immunodeficiency, thus
creating vaccine strains that will in principle be safe for widespread use in human populafions. In addifion,
we will use the incorporation of chemical adjuvants into live mycobacterial vaccine strains and several
approaches to boosting of secondary responses to further enhance vaccine-induced protection against
tuberculosis. Three specific aims are proposed: 1) Assess the impact of mutations In M. tuberculosis that
enhance apoptosis of infected host cells on T cell responses; 2) Identify and characterize mutants of M.
tuberculosis that enhance antigen presentation by MHC class 11; 3) Combine genetic modifications with
chemical adjuvants and boosting strategies to enhance T cell response and protective efficacy induced by
attenuated M. tuberculosis vaccine strains. The long term goal of these studies is to establish principles that
will lead to safer and more effecfive live M. tuberculosis vaccines that will contribute to controlling the global
burden of tuberculosis and to reducing the emergence of multidrug resistant strains. This project relates to
the overall goals of this program project by seeking to improve the immunogenicity of live attenuated M.
tuberculosis vaccines, and by establishing correlates of protection through the analysis of specific cellular
immune responses. Extensive interactions with other components of the POl funded program are
proposed, and the project will benefit sianificantiv from the various core resources supported bv the POl.
RELEVANCE (See instructions):
This proposal is an integral component of a program that aims to understand in greater detail the
mechanisms by which Mycobacterium tuberculosis evades host immunity to cause serious disease and
mortality. The goal of the research is to establish principles that will enable the design and construction of
better vaccines for the prevention of tuberculosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Flow Cytometery and Cell Sorting Core
-
批准号:10659181
-
项目类别:
-
资助金额:$21.09万
-
财政年份:2022
-
负责人:Steven A Porcelli
-
依托单位:
Flow Cytometery and Cell Sorting Core
-
批准号:10408970
-
项目类别:
-
资助金额:$21.52万
-
财政年份:2022
-
负责人:Steven A Porcelli
-
依托单位:
Bigfoot Multispectral High Speed Fluorescence Activated Cell Sorter
-
批准号:10414835
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2022
-
负责人:Steven A Porcelli
-
依托单位:
"Determinants of T Cell Immunity to Tuberculosis Vaccines"
-
批准号:8871648
-
项目类别:
-
资助金额:$7.17万
-
财政年份:2015
-
负责人:Steven A Porcelli
-
依托单位:
Flow Cytometry Core
-
批准号:8871652
-
项目类别:
-
资助金额:$2.34万
-
财政年份:2015
-
负责人:Steven A Porcelli
-
依托单位:
Construction of safe and effective live tuberculosis vaccines
-
批准号:8230473
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Defining the Correlates of Bactericidal Immunity in Tuberculosis
-
批准号:8031491
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Construction of safe and effective live tuberculosis vaccines
-
批准号:8626351
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Construction of safe and effective live tuberculosis vaccines
-
批准号:8083413
-
项目类别:
-
资助金额:$41.5万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Flow Cytometry Core
-
批准号:8049861
-
项目类别:
-
资助金额:$19.94万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Defining the Correlates of Bactericidal Immunity in Tuberculosis
-
批准号:8207834
-
项目类别:
-
资助金额:$20.81万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Construction of safe and effective live tuberculosis vaccines
-
批准号:8431439
-
项目类别:
-
资助金额:$39.01万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Construction of safe and effective live tuberculosis vaccines
-
批准号:9132485
-
项目类别:
-
资助金额:$19.09万
-
财政年份:2011
-
负责人:Steven A Porcelli
-
依托单位:
Flow Cytometry Core
-
批准号:7943653
-
项目类别:
-
资助金额:$2.84万
-
财政年份:2010
-
负责人:Steven A Porcelli
-
依托单位:
Digital Extra Parameter (DxP8)
-
批准号:7794342
-
项目类别:
-
资助金额:$11.96万
-
财政年份:2010
-
负责人:Steven A Porcelli
-
依托单位:
Laser Scanning Cytometer
-
批准号:7595975
-
项目类别:
-
资助金额:$39.84万
-
财政年份:2008
-
负责人:Steven A Porcelli
-
依托单位:
MoFlow High Speed Fluorescence Activated Cell Sorter
-
批准号:7213177
-
项目类别:
-
资助金额:$43.16万
-
财政年份:2007
-
负责人:Steven A Porcelli
-
依托单位:
FLOW CYTOMETRY SHARED RESOURCE
-
批准号:7506847
-
项目类别:
-
资助金额:$13.83万
-
财政年份:2007
-
负责人:Steven A Porcelli
-
依托单位:
Prevention of Diabetes with Lipid Immunomodulators
-
批准号:6827496
-
项目类别:
-
资助金额:$22.96万
-
财政年份:2004
-
负责人:Steven A Porcelli
-
依托单位:
Determinants of T Cell Immunity to Tuberculosis Vaccines
-
批准号:6878900
-
项目类别:
-
资助金额:$25.82万
-
财政年份:2004
-
负责人:Steven A Porcelli
-
依托单位:
海外基金